A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. - Wikidata - wikimedia - TriplyDB

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

http://www.wikidata.org/entity/Q37675882

about

Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging Development of computational small animal models and their applications in preclinical imaging and therapy research Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.Two-Step Delivery: Exploiting the Partition Coefficient Concept to Increase Intratumoral Paclitaxel Concentrations In vivo Using Responsive Nanoparticles.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis.Immunotherapies targeting CD38 in Multiple Myeloma.Standardisation of minimal residual disease in multiple myeloma.New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma.CD38 bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B cell malignancies.Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab.Immunotherapy Strategies Against Multiple Myeloma.Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.Whither Radioimmunotherapy: To Be or Not To Be?The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting.

P2860

Q27023605-3BE8B3DE-3E9A-4868-9FC0-A6C1AEB1634F Q28071642-E504DE8D-799E-498D-A128-FB919305B121 Q35220659-6F1B75A0-5E9D-4826-9978-0BF5A46CF753 Q36395999-F03AA632-3E90-4A94-A07A-7EF4161635FC Q36438435-2BB61D96-EF05-49AE-B5C5-05A1E80E2DDF Q38672091-CDE949FF-11B5-4B4B-9FE5-6499BE6F19A5 Q38799356-1AB81052-F2AC-4F05-B8D8-F07966E761D4 Q39014347-3F54F278-95CA-415C-8322-96BC822C2362 Q39045031-D0D9FB6F-65C2-4FC0-9678-DBD87F1F5F14 Q39410899-9D512971-79CD-42AB-8A69-F3527FFD02F6 Q43065347-472578F2-7884-4EE3-8EED-6E36D1FE8856 Q47329597-B06E7436-F4C1-4523-BC52-13C1E2FDB101 Q49358494-DC127F4B-9973-457A-84C4-2F70D2BE0A24 Q49950717-09BB4F00-9C8E-4650-A7F1-B7C79ED7697D Q49995864-D50927D9-89D5-40D5-8558-CE172FD5934A Q50200754-2BE00658-20B3-4212-B842-73048B846AB1 Q50203410-976B64EA-7038-4ED7-87D3-59436B3BDD9A Q53271932-52EDC0AF-BD0B-491D-AE34-93AAE1638891

P2860

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

http://www.wikidata.org/entity/Q37675882

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

@en

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

@nl

type

label

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

@en

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

@nl

prefLabel

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

@en

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

@nl

P1433

Q37675882-5FC8F617-6A67-417C-8CB8-5D10865A2168

P1476

Q37675882-A3BC600B-0C02-4353-AA9D-8541C2006567

P2093

Q37675882-020D9A4F-3B1B-48FD-A0A4-C8BFFF513471

Q37675882-05FB4150-70CE-493C-AF55-76E94C85BA7D

Q37675882-11495F4A-429B-4A8E-B6DD-CA4EF85E6872

Q37675882-49C08948-693C-462A-B876-DF8386989E57

Q37675882-66F3038C-DC1B-4020-9555-41A4D92FDAC1

Q37675882-6C30D726-F446-4ADD-88CA-896C9AA6096C

Q37675882-6E21CD2F-0CE9-48F3-9C7A-3BB6D2BAE49D

Q37675882-98205279-A4D7-43F9-83DB-60966559E0AF

Q37675882-B256EB97-5BC1-4113-82FD-A844AE8EC49A

Q37675882-BC2DD23E-7999-43F3-8484-C360D4BA49D4

P2860

Q37675882-035E2B45-84BD-4B4F-9E52-BBBFC0B4E0ED

Q37675882-06E888CE-8BDC-4D22-B323-6E29590C5924

Q37675882-0A415DA5-15AE-46C8-BB99-AD072BE39F64

Q37675882-0AD9B86B-1348-49D8-AE6B-BC6A167B5E7B

Q37675882-0D688843-37F7-43FB-B031-37F7F6031661

Q37675882-0E14F333-CCC0-4191-97C1-26B90EE81FBA

Q37675882-0FE58DE7-140D-48E9-B6C6-1B595F7DF802

Q37675882-1DF6B79D-AA1D-4649-BD4E-8768A868EE42

Q37675882-206C5E7C-BDA8-4F75-9A0D-9D2EB3312097

Q37675882-26C48C0E-B7D2-4292-AE4E-2633EA28D82C

P304

Q37675882-89E95E9B-2939-44AA-A9A5-28FD16256A02

P31

Q37675882-62A305FE-1F24-4843-8B33-B7ED2EF5C5E5

P356

Q37675882-A1550DBB-F0BB-4FA5-AF37-D3ABD5E68362

P407

Q37675882-FE61CC80-6C8B-4486-930B-0FAA8A0F7436

P433

Q37675882-67FB27CF-D1B7-41BE-BCB3-8BCFA07DF988

P478

Q37675882-B16059B3-BF4C-493A-B730-F52C74E4B66B

P50

Q37675882-9A774240-B81E-4D37-A582-02ACFA0DCE3C

Q37675882-D979AFCA-8C01-483E-8480-C0773205EED7

P577

Q37675882-17926300-A863-4BA5-9B9D-C3521F8122BF

P698

Q37675882-75C9CB00-B9A6-4BDA-A8E1-2A71B68D4B92

P932

Q37675882-1A4A11B9-F665-4DE3-BAF6-2088AF8F9943

P356

0008-5472.CAN-13-1589

P1433

Cancer Research

P1476

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies

@en

P2093

Aimee L Kenoyer

http://www.w3.org/2001/XMLSchema#string

Brent L Wood

http://www.w3.org/2001/XMLSchema#string

D S Wilbur

http://www.w3.org/2001/XMLSchema#string

Damian J Green

http://www.w3.org/2001/XMLSchema#string

Darrell R Fisher

http://www.w3.org/2001/XMLSchema#string

Donald K Hamlin

http://www.w3.org/2001/XMLSchema#string

John M Pagel

http://www.w3.org/2001/XMLSchema#string

Johnnie J Orozco

http://www.w3.org/2001/XMLSchema#string

Jon C Jones

http://www.w3.org/2001/XMLSchema#string

Mark D Hylarides

http://www.w3.org/2001/XMLSchema#string

P2860

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance

Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics

Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy.

A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.

Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.

Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

P304

1179-1189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-13-1589

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24371230

http://www.w3.org/2001/XMLSchema#string

P932

3970848

http://www.w3.org/2001/XMLSchema#string